Mangoceuticals, Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, MGRX reported earnings of -0.69 USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached 80.00 thousand, compared to an expected --, with a --% difference. The market reacted with a -14.86% price change (close before vs. close after earnings).
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Mangoceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Mangoceuticals, Inc. Common Stock reported EPS of -$0.69, missing estimates by --, and revenue of $80.00K, -- -- expectations.
How did the market react to Mangoceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -14.86%, changed from $1.48 before the earnings release to $1.26 the day after.
When is Mangoceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 20, 2026.
What are the forecasts for Mangoceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, Mangoceuticals, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q4 2025.